PLN-101095
Muscular Dystrophies
Key Facts
About Pliant Therapeutics
Pliant Therapeutics is a clinical-stage biotech focused on discovering and developing breakthrough therapies for fibrotic diseases, a class of serious conditions with high unmet medical need. The company's scientific foundation is built on targeting tissue-specific integrins to inhibit TGF-β activation, aiming for a superior therapeutic profile compared to broad TGF-β inhibitors. Its lead asset, bexotegrast, has demonstrated promising Phase 2a data in IPF and PSC, positioning the company to potentially address multi-billion dollar markets. Pliant's strategy leverages a proprietary integrin platform to build a pipeline of oral therapies for fibrosis across multiple organs.
View full company profileAbout Pliant Therapeutics
Pliant Therapeutics is a clinical-stage biotech focused on discovering and developing breakthrough therapies for fibrotic diseases, a class of serious conditions with high unmet medical need. The company's scientific foundation is built on targeting tissue-specific integrins to inhibit TGF-β activation, aiming for a superior therapeutic profile compared to broad TGF-β inhibitors. Its lead asset, bexotegrast, has demonstrated promising Phase 2a data in IPF and PSC, positioning the company to potentially address multi-billion dollar markets. Pliant's strategy leverages a proprietary integrin platform to build a pipeline of oral therapies for fibrosis across multiple organs.
View full company profileTherapeutic Areas
Other Muscular Dystrophies Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Antibody Programs | MLAB Biosciences | Pre-clinical |